Drug
Avadomide clinical trials
Also written CC-122.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Name
Development codes
- CC-122
- 12
Studies by the year they started
13 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 3 |
| 2019 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 1
Celgene (11) · Bristol-Myers Squibb (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
Often tested with
Tested in the same studies.
Nivolumab (2) · Obinutuzumab (1) · CC-223 (1) · Spebrutinib (1) · Sorafenib (1)
Studies
Open first, then newest update. How each study uses avadomide is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Rollover Study of CC-122Active, not recruitingPhase 1Bristol-Myers SquibbNCT05688475Written as CC-122
- A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)TerminatedPhase 1CelgeneNCT02509039Written as CC-122
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular LymphomaTerminatedPhase 1CelgeneNCT02031419Written as CC-122
- Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple MyelomaCompletedPhase 1CelgeneNCT01421524Written as CC-122
- A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.CompletedPhase 1CelgeneNCT02417285Written as CC-122
- Avadomide (CC-122) in Combination With Nivolumab in Advanced MelanomaCompletedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT03834623Written as CC-122
- A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)CompletedPhase 1/2CelgeneNCT02859324Written as CC-122
- Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk FactorsCompletedPhase 1CelgeneNCT03283202Written as Avadomide (CC-122)
- Radiolabeled Study of CC-122 in Healthy SubjectsCompletedPhase 1CelgeneNCT02234999Written as CC-122
- Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect StudyCompletedPhase 1CelgeneNCT02049528Written as CC-122
- Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122CompletedPhase 1CelgeneNCT03340662Written as CC-122
- A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal ImpairmentCompletedPhase 1CelgeneNCT03097016Written as CC-122
- Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver CancerTerminatedPhase 1CelgeneNCT02323906Written as CC-122
Given in every arm · 2 — avadomide is usual care beside what is tested
- A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesCompletedPhase 1/2CelgeneNCT03310619Written as CC-122
- A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedPhase 1/2CelgeneNCT02406742Written as CC-122
Codes
What other systems call avadomide · ClinicalTrials.gg INT000334
- UNII (FDA) 28DZS29F59AVADOMIDEConfirmed FDA, Wikidata
- Wikidata Q105334256avadomideConfirmed FDA, Wikidata
- NCI Thesaurus C160786AvadomideOne source FDA
- DrugBank DB14857One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 28DZS29F59 | AVADOMIDE | Confirmed FDA, Wikidata |
| Wikidata | Q105334256 | avadomide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C160786 | Avadomide | One source FDA |
| DrugBank | DB14857 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.